Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (1)
Type
(
1 selected
)
Type
Guidance (96)
Guidance programme
Guidance programme
Technology appraisal guidance (96)
Apply filters
Showing 1 to 25 of 96
cancer
Remove cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung
cancer
[ID6339]
Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal
cancer
after 1 to 3 previous treatments TS ID 11830
Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate
cancer
TS ID 11967
Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast
cancer
ID 6200
Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung
cancer
[ID3894]
Technology appraisal guidance
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck
cancer
[ID4052]
Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate
cancer
after 1 therapy [ID6203]
Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast
cancer
[ID6152]
Technology appraisal guidance
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial
cancer
TSID 10710
Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast
cancer
TS ID 11769
Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate
cancer
after 1 hormonal treatment [ID6387]
Technology appraisal guidance
Capivasertib with paclitaxel for untreated metastatic triple-negative breast
cancer
[ID6383]
Technology appraisal guidance
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate
cancer
TSID 12045
Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast
cancer
[ID6435]
Technology appraisal guidance
Datopotamab deruxtecan for treating advanced non-small-cell lung
cancer
after platinum-based chemotherapy TS ID 11840
Technology appraisal guidance
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate
cancer
TS ID 11933
Technology appraisal guidance
Dostarlimab with carboplatin and paclitaxel for untreated recurrent or advanced endometrial
cancer
with high microsatellite stability or mismatch repair proficiency ID6415
Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal
cancer
[ID6311]
Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial
cancer
with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]
Technology appraisal guidance
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder
cancer
[ID6168]
Technology appraisal guidance
Durvalumab for treating limited-stage small-cell lung
cancer
after chemoradiation [ID5073]
Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction
cancer
[ID6374]
Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal
cancer
before and after surgery [ID6254]
Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder
cancer
after resection of papillary tumours in people previously untreated with BCG [ID 5080]
Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder
cancer
when cisplatin is unsuitable TS ID 11989
Technology appraisal guidance
Current page
1
2
3
4
Page
1
of
4
Next page
Results per page
10
25
50
All
Back to top